Baricitinib in New-onset Type 1 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

October 30, 2020

Primary Completion Date

January 30, 2023

Study Completion Date

May 6, 2024

Conditions
Type 1 Diabetes
Interventions
DRUG

Baricitinib

Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. Two-thirds of participants will receive Baricitinib.

DRUG

Placebo

Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. One-third of participants will receive Placebo.

Trial Locations (4)

3050

Royal Melbourne Hospital, Parkville

3052

Royal Children's Hospital Melbourne, Parkville

3065

St Vincent's Hospital Melbourne, Fitzroy

5006

Women's and Children's Hospital Adelaide, North Adelaide

Sponsors
All Listed Sponsors
collaborator

Juvenile Diabetes Research Foundation Australia

UNKNOWN

collaborator

Juvenile Diabetes Research Foundation

OTHER

lead

St Vincent's Institute of Medical Research

OTHER